Rotavirus, Live

Summary

Rotavirus, Live (CHEMBL6068358) is an approved vaccine component; indicated across 2 conditions including rotavirus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068358
Name	Rotavirus, Live
Type	Vaccine component
Max phase	4

Also known as: Rotateq, Rotavirus, live, ROTAVIRUS, LIVE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Rotavirus infection	4	MONDO:0005194	EFO:0002622

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	7
PHASE4	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00740935	PHASE4	COMPLETED	Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.
NCT02847026	PHASE4	COMPLETED	Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study
NCT06736041	PHASE3	ACTIVE_NOT_RECRUITING	Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181	PHASE3	ACTIVE_NOT_RECRUITING	Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194	PHASE3	ACTIVE_NOT_RECRUITING	Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT01341639	PHASE3	COMPLETED	Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
NCT01839175	PHASE3	COMPLETED	Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
NCT02193061	PHASE3	COMPLETED	Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs
NCT04481191	PHASE3	COMPLETED	Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)
NCT00880698	PHASE2	COMPLETED	Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
NCT00836498	PHASE1	TERMINATED	A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).